Screening and Interventional Clinical Trials
Screening should identify cancers at an early stage, before they are clinically evident. Treatment would therefore be more effective, surgery less disfiguring, and there would be a greater likelihood that the cancer will not have spread. To be valid, a screening tool must be easy, convenient, cost-effective, widely available and safe, and it must show a benefit for the participant. With NCI support, the American College of Radiology Imaging Network (ACRIN) has conducted a number of Screening and Interventional Clinical Trials.
Paula M. Jacobs, Ph.D., is Associate Director, Cancer Imaging Program in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. She came to work at the NCI after 30 years in the pharmaceutical and medical device industries where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. More…